1-20 of 36
Merrill J. Egorin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Anastasios Stathis, Sebastien J. Hotte, Eric X. Chen, Holger W. Hirte, Amit M. Oza, Patricia Moretto, Sheila Webster, Anne Laughlin, Lee-Anne Stayner, Shauna McGill, Lisa Wang, Wen-jiang Zhang, Igor Espinoza-Delgado, Julianne L. Holleran, Merrill J. Egorin, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1582–1590.
https://doi.org/10.1158/1078-0432.CCR-10-1893
Published: 15 March 2011
View article titled, Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Open the PDF for Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas in another window
Includes: Supplementary data
Journal Articles

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors

Marwan G. Fakih, Gerald Fetterly, Merrill J. Egorin, Josephia R. Muindi, Igor Espinoza-Delgado, James A. Zwiebel, Alan Litwin, Julianne L. Holleran, Kangsheng Wang, Robert B. Diasio
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3786–3794.
https://doi.org/10.1158/1078-0432.CCR-10-0547
Published: 14 July 2010
View article titled, A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
Open the PDF for A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors in another window
Journal Articles

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Ulka N. Vaishampayan, Angelika M. Burger, Edward A. Sausville, Lance K. Heilbrun, Jing Li, M. Naomi Horiba, Merrill J. Egorin, Percy Ivy, Simon Pacey, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3795–3804.
https://doi.org/10.1158/1078-0432.CCR-10-0503
Published: 14 July 2010
View article titled, Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin
Open the PDF for Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin in another window
Journal Articles

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

Ashraf Badros, Angelika M. Burger, Sunita Philip, Ruben Niesvizky, Sarah S. Kolla, Olga Goloubeva, Carolynn Harris, James Zwiebel, John J. Wright, Igor Espinoza-Delgado, Maria R. Baer, Julianne L. Holleran, Merrill J. Egorin, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5250–5257.
https://doi.org/10.1158/1078-0432.CCR-08-2850
Published: 12 August 2009
View article titled, Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Open the PDF for Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma in another window
Journal Articles

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer

Marwan G. Fakih, Lakshmi Pendyala, Gerald Fetterly, Karoli Toth, James A. Zwiebel, Igor Espinoza-Delgado, Alan Litwin, Youcef M. Rustum, Mary Ellen Ross, Julianne L. Holleran, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3189–3195.
https://doi.org/10.1158/1078-0432.CCR-08-2999
Published: 30 April 2009
View article titled, A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Open the PDF for A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer in another window
Journal Articles

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

Archie N. Tse, David S. Klimstra, Mithat Gonen, Manish Shah, Tahir Sheikh, Rachel Sikorski, Richard Carvajal, Janet Mui, Caroll Tipian, Eileen O'Reilly, Ki Chung, Robert Maki, Robert Lefkowitz, Karen Brown, Katia Manova-Todorova, Nian Wu, Merrill J. Egorin, David Kelsen, Gary K. Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6704–6711.
https://doi.org/10.1158/1078-0432.CCR-08-1006
Published: 16 October 2008
View article titled, A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors
Open the PDF for A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine

Jan H. Beumer, Julie L. Eiseman, Robert A. Parise, Erin Joseph, Joseph M. Covey, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3529–3535.
https://doi.org/10.1158/1078-0432.CCR-07-4885
Published: 02 June 2008
View article titled, Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine
Open the PDF for Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine in another window
Journal Articles

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

Suresh S. Ramalingam, Merrill J. Egorin, Ramesh K. Ramanathan, Scot C. Remick, Rachel P. Sikorski, Theodore F. Lagattuta, Gurkamal S. Chatta, David M. Friedland, Ronald G. Stoller, Douglas M. Potter, S. Percy Ivy, Chandra P. Belani
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3456–3461.
https://doi.org/10.1158/1078-0432.CCR-07-5088
Published: 02 June 2008
View article titled, A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies in another window
Journal Articles

Population Pharmacokinetc/Pharmacodynamic Modeling of Paclitaxel and Carboplatin in Ovarian Cancer

Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2517.
https://doi.org/10.1158/1078-0432.CCR-07-5049
Published: 15 April 2008
View article titled, Population Pharmacokinetc/Pharmacodynamic Modeling of Paclitaxel and Carboplatin in Ovarian Cancer
Open the PDF for Population Pharmacokinetc/Pharmacodynamic Modeling of Paclitaxel and Carboplatin in Ovarian Cancer in another window
Journal Articles

Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors

Yaqoob Ali, Yong Lin, Mecide M. Gharibo, Murugesan K. Gounder, Mark N. Stein, Theodore F. Lagattuta, Merrill J. Egorin, Eric H. Rubin, Elizabeth A. Poplin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5876–5882.
https://doi.org/10.1158/1078-0432.CCR-07-0883
Published: 01 October 2007
View article titled, Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors in another window
Journal Articles

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

Chris H. Takimoto, Martin A. Graham, Graham Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel L. Mulkerin, Percy Ivy, Merrill J. Egorin, Jean L. Grem
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4832–4839.
https://doi.org/10.1158/1078-0432.CCR-07-0475
Published: 15 August 2007
View article titled, Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function
Open the PDF for Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function in another window
Journal Articles

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

Suresh S. Ramalingam, Robert A. Parise, Ramesh K. Ramananthan, Theodore F. Lagattuta, Lori A. Musguire, Ronald G. Stoller, Douglas M. Potter, Athanassios E. Argiris, James A. Zwiebel, Merrill J. Egorin, Chandra P. Belani
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3605–3610.
https://doi.org/10.1158/1078-0432.CCR-07-0162
Published: 15 June 2007
View article titled, Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies in another window
Journal Articles

A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871

Lionel D. Lewis, Antonius A. Miller, Gary L. Rosner, Jonathan E. Dowell, Manuel Valdivieso, Mary V. Relling, Merrill J. Egorin, Robert R. Bies, Donna R. Hollis, Ellis G. Levine, Gregory A. Otterson, Frederick Millard, Mark J. Ratain, for the Cancer and Leukemia Group B
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3302–3311.
https://doi.org/10.1158/1078-0432.CCR-06-2345
Published: 01 June 2007
View article titled, A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871
Open the PDF for A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 in another window
Journal Articles

Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors

Julie L. Eiseman, Jianxia Guo, Ramesh K. Ramanathan, Chandra P. Belani, David B. Solit, Howard I. Scher, S. Percy Ivy, Eleanor G. Zuhowski, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2121–2127.
https://doi.org/10.1158/1078-0432.CCR-06-2286
Published: 02 April 2007
View article titled, Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors
Open the PDF for Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

David B. Solit, S. Percy Ivy, Catherine Kopil, Rachel Sikorski, Michael J. Morris, Susan F. Slovin, W. Kevin Kelly, Anthony DeLaCruz, Tracy Curley, Glenn Heller, Steven Larson, Lawrence Schwartz, Merrill J. Egorin, Neal Rosen, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1775–1782.
https://doi.org/10.1158/1078-0432.CCR-06-1863
Published: 15 March 2007
View article titled, Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
Open the PDF for Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study

Rochelle Bagatell, Lia Gore, Merrill J. Egorin, Richard Ho, Glenn Heller, Nichole Boucher, Eleanor G. Zuhowski, James A. Whitlock, Stephen P. Hunger, Aru Narendran, Howard M. Katzenstein, Robert J. Arceci, Jessica Boklan, Cynthia E. Herzog, Luke Whitesell, S. Percy Ivy, Tanya M. Trippett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1783–1788.
https://doi.org/10.1158/1078-0432.CCR-06-1892
Published: 15 March 2007
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of 17-<em>N</em>-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of 17-<em>N</em>-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study in another window
Journal Articles

Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers

Ramesh K. Ramanathan, Merrill J. Egorin, Julie L. Eiseman, Suresh Ramalingam, David Friedland, Sanjiv S. Agarwala, S. Percy Ivy, Douglas M. Potter, Gurkamal Chatta, Eleanor G. Zuhowski, Ronald G. Stoller, Cynthia Naret, Jianxia Guo, Chandra P. Belani
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1769–1774.
https://doi.org/10.1158/1078-0432.CCR-06-2233
Published: 15 March 2007
View article titled, Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers
Open the PDF for Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers in another window
Journal Articles

Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice

Jan H. Beumer, Julie L. Eiseman, Robert A. Parise, Erin Joseph, Julianne L. Holleran, Joseph M. Covey, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (24): 7483–7491.
https://doi.org/10.1158/1078-0432.CCR-06-1250
Published: 22 December 2006
View article titled, Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice
Open the PDF for Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice in another window
Journal Articles

Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis

Zejia Yang, Lisa M. Schumaker, Merrill J. Egorin, Eleanor G. Zuhowski, Zhongmin Guo, Kevin J. Cullen
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5817–5825.
https://doi.org/10.1158/1078-0432.CCR-06-1037
Published: 04 October 2006
View article titled, Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis
Open the PDF for Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis in another window
Journal Articles

A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice

Jan H. Beumer, Erin Joseph, Merrill J. Egorin, Robert S. Parker, David Z. D'argenio, Joseph M. Covey, Julie L. Eiseman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5826–5833.
https://doi.org/10.1158/1078-0432.CCR-06-1234
Published: 04 October 2006
View article titled, A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice
Open the PDF for A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice in another window